Q1 2027 Gland Pharma Ltd Earnings Call Transcript
Key Points
- Strong financial performance with 20% YoY revenue growth and 47% YoY PAT growth in Q1 FY27.
- CDMO business remains a key growth driver, contributing 50% of total revenue with 20% YoY growth.
- Secured a strategic manufacturing and supply agreement with a leading global pharma company, expected to generate USD 90-100 million in revenue from CY 2029.
- Entered a strategic collaboration with Neuland Laboratories for sterile APIs for microparticle depot products, enhancing complex injectable capabilities.
- In-licensed a niche liposomal product for US and EU markets, with potential for additional products from the partner's pipeline.
- Rest of the world (ROW) markets revenue was flat YoY due to supply disruptions in Saudi Arabia and delayed Nucor tenders.
- Cenexi's performance was impacted by a summer heat wave in Europe, causing disruptions in activities and quality releases.
- GLP-1 revenue contribution is expected to be very limited in the near term, with major volumes not anticipated until FY30-31.
- The new strategic manufacturing agreement will not generate revenue until CY 2029, with technology transfer taking two years.
- The liposomal product collaboration is expected to contribute meaningful revenue only from FY30, indicating a long wait for returns.
Ladies and gentlemen, good day, and welcome to the Gland Pharma Limited Q1 FY27 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Shriniwas P. Dange, Investor Relations at Gland Pharma Limited. Thank you, and over to you, sir.
Thank you, Darwin. Good evening, everyone. We welcome you to Gland Pharma earnings conference call for Q1 of FY27. I'm Shriniwas Dange, from the Investor Relations team at Gland Pharma.
Today, we have Mr. Srinivas Sadu, Executive Chairman; and Mr. Ravi Mitra, Chief Financial Officer from India Office. We will begin the call with the business and operational highlights from Mr. Sadu, followed by the group financial overview by Mr. Ravi.
Before we proceed, I would like to remind everyone that some of the statements made today will be forward-looking and are based on management's current estimates. These statements should be considered in light of the risks
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
